Home

Pfizer (PFE)

25.19
+0.15 (0.60%)
NYSE · Last Trade: Dec 20th, 12:16 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close25.04
Open25.01
Bid25.20
Ask25.25
Day's Range24.98 - 25.52
52 Week Range20.92 - 27.69
Volume87,590,000
Market Cap141.23B
PE Ratio (TTM)14.65
EPS (TTM)1.7
Dividend & Yield1.720 (6.83%)
1 Month Average Volume53,110,935

Chart

About Pfizer (PFE)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More

News & Press Releases

The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold earlier this year, Lilly has transcended the traditional boundaries of a "Big Pharma" company to become a high-growth technology-like play on human longevity and [...]
Via PredictStreet · December 18, 2025
Deep Dive: Windlas Biotech Limited – A Pharmaceutical Growth Story
As of December 16, 2025, Windlas Biotech Limited (NSE: WINDLAS, BSE: 543403) stands as a significant player in India's burgeoning pharmaceutical sector, primarily recognized for its robust contract development and manufacturing organization (CDMO) services. Established in 2001, the company has carved a niche as one of the top five domestic pharmaceutical formulations CDMO providers by [...]
Via PredictStreet · December 16, 2025
Better Buy in 2026: Pfizer or Merck?fool.com
This year has been one to forget for these pharmaceutical giants.
Via The Motley Fool · December 19, 2025
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giantsstocktwits.com
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.
Via Stocktwits · December 19, 2025
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trumpinvestors.com
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.
Via Investor's Business Daily · December 19, 2025
Friday's session: most active stock in the S&P500 indexchartmill.com
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · December 19, 2025
Down 80%, Should You Buy the Dip on Moderna?fool.com
Your decision on whether to invest now depends to some extent on your investment strategy.
Via The Motley Fool · December 19, 2025
1 S&P 500 Stock with Impressive Fundamentals and 2 That Underwhelm
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Via StockStory · December 18, 2025
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Nowfool.com
The stocks listed here trade at forward earnings multiples of less than 18.
Via The Motley Fool · December 18, 2025
Better Buy in 2026: Pfizer or Eli Lilly?fool.com
These two stocks have been going in opposite directions over the past few years.
Via The Motley Fool · December 18, 2025
Flying Blind: How the Record 43-Day Shutdown Blinded the Fed and Rattled Global Markets
The United States economy is finally emerging from a period of unprecedented statistical darkness. Following the conclusion of the longest government shutdown in American history—a 43-day impasse that paralyzed Washington from October 1 to November 12, 2025—the release of the November Consumer Price Index (CPI) data today, December
Via MarketMinute · December 18, 2025
Industry Comparison: Evaluating Pfizer Against Competitors In Pharmaceuticals Industryindustry-com
Via Benzinga · December 18, 2025
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning.
By Pfizer Inc. · Via Business Wire · December 18, 2025
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosunbenzinga.com
Via Benzinga · December 18, 2025
The Emotional Rollercoaster: How Fear and Greed Shape Investor Behavior in Market Downturns
The financial markets, often perceived as bastions of rational decision-making, are, in reality, deeply swayed by the powerful currents of human emotion. As the global economy navigates its inherent cycles, the interplay of fear and greed emerges as a dominant force, particularly during periods of market downturns. This psychological phenomenon
Via MarketMinute · December 17, 2025
These 2 Healthcare Stocks Just Declared Dividend Raisesfool.com
The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.
Via The Motley Fool · December 17, 2025
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talksstocktwits.com
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.
Via Stocktwits · December 17, 2025
Curious about the most active S&P500 stocks in today's session?chartmill.com
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · December 17, 2025
Moderna (MRNA) Stock Trades Up, Here Is Why
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry. 
Via StockStory · December 17, 2025
If I Could Only Buy and Hold a Single Stock, This Would Be Itfool.com
Pfizer's shares look attractive to investors willing to show patience.
Via The Motley Fool · December 17, 2025
FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuitbenzinga.com
FDA approves a new Depo-Provera warning on meningioma risk as Pfizer faces lawsuits alleging delayed disclosure of brain tumor concerns.
Via Benzinga · December 17, 2025
Nasdaq Navigates Choppy Waters: Tech Index Shows Resilience Amidst Volatility and AI Bubble Concerns
The Nasdaq Composite (IXIC) has been on a rollercoaster ride as 2025 draws to a close, experiencing a notable three-day losing streak before showing a modest rebound on December 17. This recent volatility has ignited discussions around an "AI bubble" and raised questions about the sustainability of the tech sector's
Via MarketMinute · December 17, 2025
Dow Jones Soars to New Highs Amidst Economic Crosscurrents and AI Jitters
New York, NY – December 17, 2025 – The Dow Jones Industrial Average (DJIA) has concluded December 2025 with a notable ascent, marking a period of robust performance that has seen the index reach new all-time record highs. This upward momentum, however, unfolds against a complex and often contradictory economic landscape, characterized
Via MarketMinute · December 17, 2025
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Backbenzinga.com
Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers reliability.
Via Benzinga · December 17, 2025
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Nowfool.com
It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.
Via The Motley Fool · December 17, 2025